Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
Mashari AlzahraniCarol StoberMichelle LiuArif AwanTerry L NgGregory PondBader AlshamsanLisa VandermeerMark ClemonsPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
The risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de-escalation and even stopping of BMAs with longer-term use may therefore be warranted.